Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Longitudinal Structural Brain Alterations in Parkinson’s Disease Patients with Freezing of Gait
Movement Disorders
Movement Disorders Posters (7:00 AM-5:00 PM)
161
The main objective of this study is to investigate the cortical and subcortical grey matter (GM) changes in Parkinson’s disease (PD) patients with freezing of gait (FoG) over one and two years of follow-up. We also investigated GM features of PD patients developing FoG (PD-FoG-converters) within two years.
Currently, no longitudinal studies have investigated the FoG changes in PD patients analyzing both clinical measurements and multimodal MRI data.

Thirty PD-FoG and 11 PD-FoG-converters patients were recruited. Patients underwent 3D T1-weighted magnetic resonance imaging. Whole brain cortical thickness and volumes of basal ganglia, thalamus, nucleus accumbens, amygdala and hippocampus were assessed. Paired t test corrected for multiple comparisons using the Bonferroni procedure at p<0.05 were used to assess GM changes over one and two years of follow-up in PD-FoG and PD-FoG-converters patients.

Both PD-FoG and PD-FoG-converters patients showed no cortical thickness changes over time. The analysis of GM volumes showed that PD-FoG patients presented decreased volume of the right putamen between baseline and one year and reduced volume of left pallidum, right thalamus and hippocampus between one and two years of follow-up. Moreover, PD-FoG-converters showed GM atrophy accumulation in the right putamen and hippocampus between baseline and two years and of the right putamen between one and two years of follow-up.

PD-FoG and PD-FoG-converters are characterized by a progressive accumulation of GM atrophy in areas involved both in motor and cognitive functions such as basal ganglia and hippocampus. These findings support the hypothesis concerning the problematic interplay between motor and cognitive circuits in the underlying mechanisms of FoG in PD.

Authors/Disclosures
Noemi Piramide, MSc (Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neu)
PRESENTER
Noemi Piramide has nothing to disclose.
Elisabetta Sarasso Elisabetta Sarasso has nothing to disclose.
Federica Agosta (San Raffaele Scientific Institute) Federica Agosta has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Philips. Federica Agosta has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier INC.
No disclosure on file
Iva Stankovic (Neurology Clinic, Clinical Center of Serbia, University of Belgrade) Iva Stankovic has nothing to disclose.
Silvia Basaia Silvia Basaia has nothing to disclose.
Alexandra Tomic No disclosure on file
Vladana Markovic No disclosure on file
Elka Stefanova No disclosure on file
Vladimir S. Kostic, MD, PhD (Institute of Neurology CCS) Dr. Kostic has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Roche. An immediate family member of Dr. Kostic has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Alkaloid. The institution of Dr. Kostic has received research support from Ministry of Âé¶¹´«Ã½Ó³»­, Science and Technological Development of Serbia.
Massimo Filippi, MD, FÂé¶¹´«Ã½Ó³»­ (Ospedale San Raffaele, Neuroimaging Research Unit) Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.